Clinical Trials Browser

Phase 1 × INDUSTRY × relatlimab × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

57 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Phase 1 Terminated

67 enrolled

Dermatologic

Uveal Melanoma

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Neoplasms

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Phase 1 Terminated

11 enrolled

Dermatologic

Melanoma

NCT05498480 2024-02-20

RELATIVITY-111

Phase 1 Completed

6 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

STELLAR-002

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

RELATIVITY-111